Ovarian cancer is one of the more pernicious and aggressive human neoplastic diseases. The condition could be more manageable if oncologists knew before the completion of chemotherapy whether treatment was having the desired effect.
Ovarian cancer is one of the more pernicious and aggressive human neoplastic diseases. The condition could be more manageable if oncologists knew before the completion of chemotherapy whether treatment was having the desired effect.
A study presented Monday at the Society of Nuclear Medicine meeting strongly suggests that FDG-PET will be the tool that could provide that information. Dr. Stefanie Sassen and colleagues at the Technical University of Munich demonstrated that changes in FDG uptake rates after one cycle of neoadjuvant therapy can predict long-term patient survival. Standard uptake value measures were even more accurate when FDG-PET was performed after three cycles.
A preliminary trial involving 33 patients, along with experience with other cancers suggesting that a 20% decline in FDG uptake indicates a positive response to therapy, formed the basis for these findings. FDG-PET imaging covering the abdomen and pelvis was performed before treatment and after the first and third cycles of carboplatin-based chemotherapy. Patients received three cycles of chemotherapy before debulking surgery. Results were monitored for three years.
Sassen and the nuclear medicine laboratory of Dr. Markus Schwaiger found significant correlation between changes in FDG-PET uptake and patient survival after the first (p = 0.008) and third (p = 0.005) cycles of therapy. Patients classified as responders survived 38.3 months compared with 23.1 months for patients classified with PET as nonresponders. Using a 55% decrease in SUV as a positive response threshold, the researchers found the overall survival of patients classified as responders with FDG-PET to be 38.9 months. It was 19.7 months for predicted nonresponders.
The study laid the foundation for larger trials to confirm the results and to apply the protocol to treatment modifications to improve patient outcomes, Sassen said.
"We found that we can predict survival by performing baseline PET and PET again after one cycle of chemotherapy. This change in metabolic activity will predict outcomes," she said.
For further information from Diagnostic Imaging:
Reducing uncertainty: PET identifies early response to therapy
PET could become go-to modality for gauging response to therapy
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.